{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:39:21Z","timestamp":1785220761965,"version":"3.55.0"},"reference-count":85,"publisher":"The Endocrine Society","issue":"9","funder":[{"DOI":"10.13039\/100005709","name":"Endocrine Society","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100005709","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>The extent to which some pharmacological interventions reduce or increase the risk of biochemical conversion to type 2 diabetes mellitus (T2DM) in at-risk individuals is unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and Scopus through 24 August 2017 for randomized controlled trials evaluating the effect of drugs suspected to modify the risk of biochemical conversion to T2DM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 43 trials with 192,156 subjects (mean age, 60 years; 56% men; mean body mass index, 30.4 kg\/m2). \u03b1-Glucosidase inhibitors, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, metformin, orlistat, phentermine\/topiramate, and pioglitazone significantly reduced the risk of biochemical conversion to T2DM, whereas statins and nateglinide increased the risk. There was insufficient direct evidence regarding the effects of sulfonylureas, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors. Most trials were brief and evaluated this outcome during treatment without a withdrawal or washout period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Several drugs modify the risk of biochemical conversation to T2DM, although whether this effect is persistent and clinically relevant is unclear. Future studies need to focus on cardiovascular disease prevention, mortality, and patient-important outcomes instead of biochemical conversion to T2DM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2019-01269","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T09:00:34Z","timestamp":1564650034000},"page":"3986-3995","source":"Crossref","is-referenced-by-count":4,"title":["Medications Affecting the Biochemical Conversion to Type 2 Diabetes: A Systematic Review and Meta-Analysis"],"prefix":"10.1210","volume":"104","author":[{"given":"Juan Pablo","family":"Domecq","sequence":"first","affiliation":[{"name":"Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Prutsky","sequence":"additional","affiliation":[{"name":"Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarig","family":"Elraiyah","sequence":"additional","affiliation":[{"name":"Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Nephrology, Department of Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen F","family":"Mauck","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Brito","sequence":"additional","affiliation":[{"name":"Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Endocrinology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitanya","family":"Undavalli","sequence":"additional","affiliation":[{"name":"Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Sundaresh","sequence":"additional","affiliation":[{"name":"Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Endocrinology, Metabolism, and Diabetes, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J","family":"Prokop","sequence":"additional","affiliation":[{"name":"Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M","family":"Montori","sequence":"additional","affiliation":[{"name":"Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota"},{"name":"Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Endocrinology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-5975","authenticated-orcid":false,"given":"M Hassan","family":"Murad","sequence":"additional","affiliation":[{"name":"Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,7,31]]},"reference":[{"issue":"8","key":"2019080109002763700_bib1","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jamainternmed.2016.2952","article-title":"What we don\u2019t talk about when we talk about preventing type 2 diabetes\u2014addressing socioeconomic disadvantage","volume":"176","author":"Spencer Bonilla","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"7","key":"2019080109002763700_bib2","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2019080109002763700_bib3","unstructured":"Domecq JP, Prutsky G, Elraiyah T, Wang Z, Mauck KF, Brito JP, Undavalli C, Sundaresh V, Prokop LJ, Montori VM, Murad MH. Data from: Medications affecting the biochemical conversion to type 2 diabetes: a systematic review and meta-analysis. figshare 2019. Deposited 4 June 2019. https:\/\/dx.doi.org\/10.6084\/m9.figshare.8224514."},{"key":"2019080109002763700_bib4","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"2019080109002763700_bib5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.mayocp.2017.01.001","article-title":"Clinical practice guidelines: a primer on development and dissemination","volume":"92","author":"Murad","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2019080109002763700_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"7414","key":"2019080109002763700_bib7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"2 Suppl","key":"2019080109002763700_bib8","doi-asserted-by":"crossref","first-page":"e185S","DOI":"10.1378\/chest.11-2289","article-title":"Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"issue":"3","key":"2019080109002763700_bib9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2337\/dc07-9920","article-title":"Impaired fasting glucose and impaired glucose tolerance: implications for care","volume":"30","author":"Nathan","year":"2007","journal-title":"Diabetes Care"},{"issue":"6","key":"2019080109002763700_bib10","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc09-1203","article-title":"Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes","volume":"33","author":"Rosenstock","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"2019080109002763700_bib11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2337\/dc07-1616","article-title":"Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance","volume":"31","author":"Rosenstock","year":"2008","journal-title":"Diabetes Care"},{"issue":"6","key":"2019080109002763700_bib12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2796.2006.01633.x","article-title":"Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance","volume":"259","author":"Eriksson","year":"2006","journal-title":"J Intern Med"},{"issue":"2","key":"2019080109002763700_bib13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1463-1326.2010.01331.x","article-title":"Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi Antidiabetes Study (NANSY)","volume":"13","author":"Lindblad","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2019080109002763700_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients [published correction appears in Diabetes Care. 2004;27(3):856]","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"issue":"10077","key":"2019080109002763700_bib15","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 Years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"key":"2019080109002763700_bib16","first-page":"CD012106","article-title":"Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus","volume":"4","author":"Hemmingsen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2019080109002763700_bib17","first-page":"CD012204","article-title":"Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus","volume":"5","author":"Hemmingsen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2019080109002763700_bib18","first-page":"CD012151","article-title":"Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus","volume":"10","author":"Hemmingsen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2019080109002763700_bib19","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1001\/jamainternmed.2017.6040","article-title":"Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials","volume":"177","author":"Haw","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"15","key":"2019080109002763700_bib20","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa065061","article-title":"Effect of ramipril on the incidence of diabetes","volume":"355","author":"Bosch","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"2019080109002763700_bib21","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.2337\/dc11-0545","article-title":"Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study","volume":"34","author":"Barzilay","year":"2011","journal-title":"Diabetes Care"},{"issue":"4","key":"2019080109002763700_bib22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ahj.2008.05.017","article-title":"Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial","volume":"156","author":"Califf","year":"2008","journal-title":"Am Heart J"},{"issue":"5","key":"2019080109002763700_bib23","first-page":"873","article-title":"Voglibose for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance [in Japanese]","volume":"68","author":"Kawamori","year":"2010","journal-title":"Nihon Rinsho"},{"issue":"9","key":"2019080109002763700_bib24","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2337\/dc06-0061","article-title":"Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program","volume":"29","author":"Kirkman","year":"2006","journal-title":"Diabetes Care"},{"issue":"2","key":"2019080109002763700_bib25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00125-005-0097-z","article-title":"The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)","volume":"49","author":"Ramachandran","year":"2006","journal-title":"Diabetologia"},{"issue":"1","key":"2019080109002763700_bib26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.104.528166","article-title":"Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure","volume":"112","author":"Yusuf","year":"2005","journal-title":"Circulation"},{"issue":"20","key":"2019080109002763700_bib27","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"351","author":"Braunwald","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"2019080109002763700_bib28","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/01.CIR.0000054611.89228.92","article-title":"Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"107","author":"Vermes","year":"2003","journal-title":"Circulation"},{"issue":"15","key":"2019080109002763700_bib29","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.286.15.1882","article-title":"Ramipril and the development of diabetes","volume":"286","author":"Yusuf","year":"2001","journal-title":"JAMA"},{"issue":"9","key":"2019080109002763700_bib30","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/diacare.19.9.920","article-title":"The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution","volume":"19","author":"Fontbonne","year":"1996","journal-title":"Diabetes Care"},{"key":"2019080109002763700_bib31","author":"Sawada"},{"issue":"8","key":"2019080109002763700_bib32","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/dmrr.839","article-title":"A study of the effects of acarbose on glucose metabolism in patients predisposed to developing diabetes: the Dutch acarbose intervention study in persons with impaired glucose tolerance (DAISI)","volume":"24","author":"Nijpels","year":"2008","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"2019080109002763700_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.106.685073","article-title":"Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery","volume":"117","author":"Rouleau","year":"2008","journal-title":"Circulation"},{"issue":"9386","key":"2019080109002763700_bib34","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"2019080109002763700_bib35","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithell","year":"2003","journal-title":"J Hypertens"},{"issue":"23","key":"2019080109002763700_bib36","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"issue":"6","key":"2019080109002763700_bib37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1464-5491.1999.00090.x","article-title":"Effect of metformin on patients with impaired glucose tolerance","volume":"16","author":"Li","year":"1999","journal-title":"Diabet Med"},{"issue":"8934","key":"2019080109002763700_bib38","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"issue":"21","key":"2019080109002763700_bib39","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"9645","key":"2019080109002763700_bib40","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"issue":"22","key":"2019080109002763700_bib41","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"issue":"9542","key":"2019080109002763700_bib42","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"Lancet"},{"key":"2019080109002763700_bib43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003495-200464002-00005","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2014Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"64","author":"Sever","year":"2004","journal-title":"Drugs"},{"issue":"10","key":"2019080109002763700_bib44","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2337\/diacare.26.10.2713","article-title":"Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial","volume":"26","author":"Keech","year":"2003","journal-title":"Diabetes Care"},{"issue":"9374","key":"2019080109002763700_bib45","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"issue":"9346","key":"2019080109002763700_bib46","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"issue":"20","key":"2019080109002763700_bib47","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"issue":"10","key":"2019080109002763700_bib48","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/archneurol.2011.146","article-title":"Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial","volume":"68","author":"Callahan","year":"2011","journal-title":"Arch Neurol"},{"issue":"12","key":"2019080109002763700_bib49","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to prevent recurrent stroke and cardiovascular events","volume":"359","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"2019080109002763700_bib50","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0168-8227(03)00117-7","article-title":"Efficacy of acarbose in Chinese subjects with impaired glucose tolerance","volume":"61","author":"Pan","year":"2003","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"2019080109002763700_bib51","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"2019080109002763700_bib52","doi-asserted-by":"crossref","first-page":"912","DOI":"10.2337\/dc13-1518","article-title":"Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"issue":"6","key":"2019080109002763700_bib53","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"issue":"9323","key":"2019080109002763700_bib54","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"issue":"16","key":"2019080109002763700_bib55","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJMoa1001122","article-title":"Effect of nateglinide on the incidence of diabetes and cardiovascular events","volume":"362","author":"Holman","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"2019080109002763700_bib56","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.CIR.103.3.357","article-title":"Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study","volume":"103","author":"Freeman","year":"2001","journal-title":"Circulation"},{"issue":"6","key":"2019080109002763700_bib57","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/fampra\/18.6.565","article-title":"The association between funding by commercial interests and study outcome in randomized controlled drug trials","volume":"18","author":"Yaphe","year":"2001","journal-title":"Fam Pract"},{"issue":"9230","key":"2019080109002763700_bib58","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(00)02605-2","article-title":"The uncertainty principle and industry-sponsored research","volume":"356","author":"Djulbegovic","year":"2000","journal-title":"Lancet"},{"issue":"15","key":"2019080109002763700_bib59","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jama.282.15.1453","article-title":"Evaluation of conflict of interest in economic analyses of new drugs used in oncology","volume":"282","author":"Friedberg","year":"1999","journal-title":"JAMA"},{"issue":"2","key":"2019080109002763700_bib60","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/archinte.1994.00420020059007","article-title":"A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis","volume":"154","author":"Rochon","year":"1994","journal-title":"Arch Intern Med"},{"issue":"9","key":"2019080109002763700_bib61","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/archinte.160.9.1321","article-title":"Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults","volume":"160","author":"Heymsfield","year":"2000","journal-title":"Arch Intern Med"},{"issue":"5","key":"2019080109002763700_bib62","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00592-014-0624-9","article-title":"Prevention of type 2 diabetes in obese at-risk subjects: a systematic review and meta-analysis","volume":"51","author":"Merlotti","year":"2014","journal-title":"Acta Diabetol"},{"issue":"8","key":"2019080109002763700_bib63","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1464-5491.2011.03303.x","article-title":"Oral anti-diabetic drugs for the prevention of type 2 diabetes","volume":"28","author":"Phung","year":"2011","journal-title":"Diabet Med"},{"issue":"9716","key":"2019080109002763700_bib64","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"2019080109002763700_bib65","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.diabres.2015.01.027","article-title":"Preventing the progression to type 2 diabetes mellitus in adults at high risk: a systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions","volume":"107","author":"Stevens","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"2019080109002763700_bib66","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","article-title":"Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes","volume":"60","author":"Griffin","year":"2017","journal-title":"Diabetologia"},{"issue":"11","key":"2019080109002763700_bib67","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/M15-2650","article-title":"Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis","volume":"164","author":"Maruthur","year":"2016","journal-title":"Ann Intern Med"},{"issue":"4","key":"2019080109002763700_bib68","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2337\/diacare.26.4.977","article-title":"Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program","volume":"26","author":"Diabetes Prevention Program Research Group","year":"2003","journal-title":"Diabetes Care"},{"issue":"4","key":"2019080109002763700_bib69","first-page":"CD005061","article-title":"Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose","author":"Van de Laar","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2019080109002763700_bib70","doi-asserted-by":"crossref","first-page":"i1541","DOI":"10.1136\/bmj.i1541","article-title":"Pioglitazone use and risk of bladder cancer: population based cohort study","volume":"352","author":"Tuccori","year":"2016","journal-title":"BMJ"},{"issue":"9","key":"2019080109002763700_bib71","first-page":"895","article-title":"Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin","volume":"20","author":"Breunig","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"2019080109002763700_bib72","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13098-017-0290-5","article-title":"Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis","volume":"9","author":"Filipova","year":"2017","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"2019080109002763700_bib73","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.metabol.2004.07.008","article-title":"Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial","volume":"54","author":"Smith","year":"2005","journal-title":"Metabolism"},{"issue":"6","key":"2019080109002763700_bib74","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2337\/dc10-1567","article-title":"Incidence of diabetes following ramipril or rosiglitazone withdrawal","volume":"34","author":"DREAM Trial Investigators","year":"2011","journal-title":"Diabetes Care"},{"issue":"12","key":"2019080109002763700_bib75","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/archinternmed.2010.182","article-title":"Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants","volume":"170","author":"Ray","year":"2010","journal-title":"Arch Intern Med"},{"issue":"13","key":"2019080109002763700_bib76","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/archinte.164.13.1427","article-title":"Effectiveness of statin therapy in adults with coronary heart disease","volume":"164","author":"Wilt","year":"2004","journal-title":"Arch Intern Med"},{"issue":"12","key":"2019080109002763700_bib77","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1007\/s00125-014-3374-x","article-title":"Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis","volume":"57","author":"Erqou","year":"2014","journal-title":"Diabetologia"},{"issue":"4","key":"2019080109002763700_bib78","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jcpt.12675","article-title":"Risk of new-onset diabetes mellitus during treatment with low-dose statins in Japan: a retrospective cohort study","volume":"43","author":"Kato","year":"2018","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"2019080109002763700_bib79","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/eurheartj\/ehr035","article-title":"Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients","volume":"32","author":"Mills","year":"2011","journal-title":"Eur Heart J"},{"issue":"1","key":"2019080109002763700_bib80","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13098-017-0272-7","article-title":"Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction","volume":"9","author":"Li","year":"2017","journal-title":"Diabetol Metab Syndr"},{"issue":"6","key":"2019080109002763700_bib81","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7326\/M15-0452","article-title":"Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force","volume":"163","author":"Balk","year":"2015","journal-title":"Ann Intern Med"},{"issue":"33","key":"2019080109002763700_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16330","article-title":"Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation","volume":"16","author":"Gillett","year":"2012","journal-title":"Health Technol Assess"},{"issue":"2","key":"2019080109002763700_bib83","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11892-010-0170-y","article-title":"Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy","volume":"11","author":"Sullivan","year":"2011","journal-title":"Curr Diab Rep"},{"issue":"7588","key":"2019080109002763700_bib84","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/bmj.39063.689375.55","article-title":"Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis","volume":"334","author":"Gillies","year":"2007","journal-title":"BMJ"},{"issue":"21","key":"2019080109002763700_bib85","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1001\/jama.299.21.2543","article-title":"Patient-important outcomes in registered diabetes trials","volume":"299","author":"Gandhi","year":"2008","journal-title":"JAMA"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/9\/3986\/29027704\/jc.2019-01269.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T03:38:41Z","timestamp":1569123521000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/9\/3986\/5540923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,31]]},"references-count":85,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2019-01269","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9]]},"published":{"date-parts":[[2019,7,31]]}}}